<DOC>
	<DOCNO>NCT00598572</DOCNO>
	<brief_summary>Animal study show breakdown blood result iron accumulation brain brain hemorrhage ( ICH ) ; iron play role brain injury ICH patient . Deferoxamine ( DFO ) extensively use clinical practice 30 year remove excessive iron body , show provide benefit animal study ICH . Therefore , plan undertake study evaluate safety tolerability treatment DFO patient ICH , determine maximal tolerate dose use future study determine treatment DFO improve outcome patient ICH . Our main objective : 1 ) evaluate safety tolerability vary dos DFO , determine treatment related adverse event , patient ICH ; 2 ) determine maximal tolerate dose adopt subsequent study test efficacy DFO improve outcome ICH . We hypothesize DFO well-tolerated minimal serious adverse effect patient ICH ; treatment DFO improve patient ' outcome . The result potentially bring account new mean improve outcome patient ICH . ICH frequent cause disability death . A successful study demonstrate efficacy iron-modifying therapy would considerable public health significance .</brief_summary>
	<brief_title>Dose Finding Safety Study Deferoxamine Patients With Brain Hemorrhage</brief_title>
	<detailed_description>An open-label , safety , tolerability , dose-finding study use continuous reassessment method .</detailed_description>
	<mesh_term>Hemorrhage</mesh_term>
	<mesh_term>Cerebral Hemorrhage</mesh_term>
	<mesh_term>Deferoxamine</mesh_term>
	<criteria>1 . Age â‰¥ 18 year 2 . The diagnosis ICH confirm brain CT scan . 3 . The first dose study drug administer within 18 hour ICH symptom onset . 4 . Signed date informed consent obtain 5 . Stable clinical neurological status . Patients whose clinical neurological status significantly deteriorate compare presentation prior administration study drug exclude . 1 . Previous chelation therapy know hypersensitivity DFO product 2 . Abnormal renal function ( serum creatinine &gt; 2 mg/dl ) 3 . Known severe iron deficiency anemia 4 . Planned surgical evacuation ICH prior administration study drug 5 . Patients suspect secondary ICH relate tumour , coagulopathy , rupture aneurysm arteriovenous malformation , venous sinus thrombosis 6 . Evidence significant shift midline brain structure ( &gt; 10 mm ) herniation image study . 7 . Deep coma ( Glasgow Coma Score ( GCS ) = 35 ) upon presentation 8 . Taking iron supplement prochlorperazine 9 . Patients heart failure take &gt; 500 mg vitamin C daily 10 . Known hear impairment 11 . Systolic blood pressure &lt; 100 mmHg diastolic blood pressure &lt; 60 mmHg , confirm 3 consecutive reading 12 . Significant chronic respiratory insufficiency 13 . Known pregnancy ( positive pregnancy test ) , breastfeed 14 . Patients know suspected able comply study protocol due alcoholism , drug dependency , incompliance , cause . 15 . Any condition , judgement investigator , might increase risk patient 16 . Life expectancy le 90 day due comorbid condition 17 . Concurrent participation another research protocol investigation another experimental therapy 18 . Preexisting Do Not Resuscitate ( DNR ) order , indication new DNR order implement within first 48 hour hospitalization .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Deferoxamine</keyword>
	<keyword>Safety</keyword>
	<keyword>Intracerebral hemorrhage</keyword>
</DOC>